Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Aptevo Therapeutics Inc (NQ: APVO )

0.2766 -0.0324 (-10.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
Via ACCESSWIRE
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Via ACCESSWIRE
Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA
Via ACCESSWIRE
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
Via ACCESSWIRE
Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024
Via ACCESSWIRE
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q2 2024
APVO stock results show that Aptevo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday! 
Via InvestorPlace
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Aptevo Therapeutics Announces Closing of $2.75 Million Offering
Via ACCESSWIRE
Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We have all of the biggest pre-market stock movers that investors are going to want to keep an eye on for Monday morning! 
Via InvestorPlace
Aptevo Participating in the BIO International Convention
Via ACCESSWIRE
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024
APVO stock results show that Aptevo Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.